<DOC>
	<DOCNO>NCT01670565</DOCNO>
	<brief_summary>This 48 week , phase IIa , single center , randomize , double-blind , placebo-controlled , proof-of-concept pilot study . All participant first treat mycophenolate mofetil ( MMF , Cellcept ) titrate dose 2 grams/day . Following period , half give either belimumab ( Benlysta® ) placebo intravenous infusion treat early diffuse cutaneous systemic sclerosis . Belimumab/MMF expect improve disease activity measure improvement skin thicken stability pulmonary function test measurement compare patient treat placebo/MMF .</brief_summary>
	<brief_title>Belimumab Treatment Diffuse Cutaneous Systemic Sclerosis</brief_title>
	<detailed_description>The specific objective study : 1 . Determine whether belimumab use combination MMF safe tolerable treatment patient early diffuse cutaneous systemic sclerosis ( Disease duration &lt; 3 year ) . 2 . Determine whether belimumab use combination MMF effective treatment diffuse cutaneous systemic sclerosis MMF alone , measure change modify Rodnan Skin Score ( mRSS ) , force vital capacity ( FVC ) , hemoglobin correct diffusion capacity ( DLCO ) , Medsger Severity Scale ( MSS ) , physician patient derive outcome measure . 3 . Determine biological activity Belimumab/MMF assess effect histology skin , change B-Cell profile , effect BLyS level , effect serological cutaneous biomarkers disease activity .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Age great equal eighteen year . 2 . Clinical diagnosis diffuse systemic sclerosis ACR criterion , stable modify Rodnan skin score one month precede introduction belimumab therapy . 3 . Disease duration less equal 3 year define date onset first nonRaynaud 's symptom . 1 . Inability render inform consent accordance institutional guideline . 2 . Disease duration great 3 year . 3 . Patients mixed connective tissue disease `` overlap '' ( i.e . satisfy one set ACR criterion rheumatic disease . ) 4 . Limited scleroderma . 5 . Systemic sclerosislike illness associate environmental ingested agent toxic rapeseed oil , vinyl chloride , bleomycin . 6 . Ongoing treatment immunosuppressive therapy include cyclophosphamide , azathioprine , methotrexate , cyclosporine , use medication within 1 month trial entry . 7 . The use antifibrotic agent include colchicine , Dpenicillamine , minocycline , tyrosine kinase inhibitor ( nilotinib , imatinib , dasatinib ) , Type 1 oral Collagen month prior enrollment . 8 . Use prior month corticosteroid dose exceed equivalent prednisone 10 mg daily . Use corticosteroid &lt; 10 mg prednisone continue course study . 9 . Treatment MMF dose ≥ 2 gram daily &gt; 3 month . 10 . Concurrent serious medical condition opinion investigator make patient inappropriate study uncontrollable CHF , arrhythmia , severe pulmonary systemic hypertension , severe GI involvement , hepatic impairment , serum creatinine great 2.0 , active infection , severe diabetes , unstable atherosclerotic cardiovascular disease , malignancy , HIV , severe peripheral vascular disease . 11 . A positive pregnancy test entry study . 12 . Men woman reproductive potential require use effective mean contraception course study , tubal ligation hysterectomy , condom diaphragm use spermicide , intrauterine device ( IUD ) . Approved hormonal contraceptive ( birth control pill , patch , implant injection ) may interact reduce effectiveness MMF thus , acceptable . Contraceptive measure Plan B ( TM ) , sell emergency use unprotected sex , acceptable method routine use . 13 . Breastfeeding . Breastfeeding contraindicate use MMF . 14 . Participation another clinical research study involve evaluation another investigational drug within ninety day entry study . 15 . The presence severe lung disease define diffusion capacity le 30 % predict require supplemental oxygen . 16 . History HIV infection 17 . Known active bacterial , viral , fungal , mycobacterial , infection r major episode infection require hospitalization treatment IV antibiotic within 4 week screen , oral antibiotic within 2 week prior screen 18 . Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication 19 . Prior use Belimumab , Rituximab , BCell deplete therapy ever 20 . The use biologics include TNF inhibitor , abatacept , tocilizumab within 1 month enrollment [ safety issue ] 21 . Patients history severe depression , psychosis , suicidal ideation exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diffuse cutaneous systemic sclerosis</keyword>
	<keyword>Early Diffuse cutaneous systemic sclerosis</keyword>
</DOC>